Literature DB >> 26511668

Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone.

W B Robb1,2,3, M Messager1,2,3, L Dahan4, F Mornex5, E Maillard6, X B D'Journo7, J-P Triboulet1,3, L Bedenne8, J-F Seitz4, C Mariette1,2,3.   

Abstract

BACKGROUND: Patterns of disease recurrence in patients with oesophageal cancer following treatment with neoadjuvant chemoradiotherapy and surgery (nCRTS) or surgery alone are poorly reported. An understanding of patterns of disease recurrence is important for subsequent treatment planning.
METHODS: An analysis was undertaken of patterns of disease recurrence from a phase III multicentre randomized trial (FFCD9901) comparing nCRTS with surgery alone in patients with stage I and II oesophageal cancer.
RESULTS: Some 170 patients undergoing surgical resection were included in the study. R0 resection rates were similar in the two groups: 94 per cent following nCRTS versus 92 per cent after surgery alone (P = 0·749). After a median follow-up of 94·2 months, recurrent disease was found in 39·4 per cent of the overall cohort (31 per cent after nCRTS versus 47 per cent following surgery alone; P = 0·030). Locoregional recurrence was diagnosed in 41 patients (17 versus 30 per cent respectively; P = 0·047) and distant metastatic recurrence in 47 (23 versus 31 per cent respectively; P = 0·244). Metastatic recurrence was more frequent in patients with adenocarcinoma than in those with squamous cell cancer (40 versus 23·1 per cent respectively; P = 0·032). ypT0 N0 category was associated with prolonged time to mixed locoregional and metastatic recurrence (P = 0·009), and time to locoregional (P = 0·044) and metastatic (P = 0·055) recurrence. In multivariable analysis, node-positive disease predicted both locoregional (P = 0·001) and metastatic (P < 0·001) recurrence.
CONCLUSION: Locoregional disease control following nCRTS indicated a local field effect not related solely to completeness of resection. pN+ disease was strongly predictive of time to locoregional and metastatic disease recurrence.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26511668     DOI: 10.1002/bjs.9959

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

1.  Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.

Authors:  Yoko Hiraki; Yutaka Kimura; Motohiro Imano; Hiroaki Kato; Mitsuru Iwama; Osamu Shiraishi; Atsushi Yasuda; Masayuki Shinkai; Tomoki Makino; Masaaki Motoori; Makoto Yamasaki; Hiroshi Miyata; Takao Satou; Taroh Satoh; Hiroshi Furukawa; Masahiko Yano; Yuichiro Doki; Takushi Yasuda
Journal:  Surg Today       Date:  2020-06-28       Impact factor: 2.549

2.  Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.

Authors:  Matthias Felix Haefner; Kristin Lang; Vivek Verma; Stefan Alexander Koerber; Lorenz Uhlmann; Juergen Debus; Florian Sterzing
Journal:  Strahlenther Onkol       Date:  2017-09-15       Impact factor: 3.621

3.  Metastatic Esophageal Carcinoma: Prognostic Factors and Survival.

Authors:  Hayam Fathy Ghazy; Hend Ahmed El-Hadaad; Hanan Ahmed Wahba; Ramy Abbas; Osama A Abbas
Journal:  J Gastrointest Cancer       Date:  2021-04-13

4.  Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Qin Lin; Zhen-Yu He
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

Review 5.  Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

Authors:  Fengxia Liu; Helin Feng; Sumin Guo; Yuhan Chen; Qingyi Liu; Feng Wu; Weikuan Gu; Baoen Shan
Journal:  J Oncol       Date:  2019-05-23       Impact factor: 4.375

6.  From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

Authors:  Qichen Chen; Rui Mao; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Hong Zhao; Jianqiang Cai
Journal:  Cancer Med       Date:  2020-09-04       Impact factor: 4.452

7.  Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer.

Authors:  Joerg Lindenmann; Melanie Fediuk; Nicole Fink-Neuboeck; Christian Porubsky; Martin Pichler; Luka Brcic; Udo Anegg; Marija Balic; Nadia Dandachi; Alfred Maier; Maria Smolle; Josef Smolle; Freyja Maria Smolle-Juettner
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

8.  Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.

Authors:  Yushi Nagaki; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Hiromu Fujita; Yoshihiro Sasaki; Kazuhiro Imai; Yoshihiro Minamiya
Journal:  BMC Cancer       Date:  2021-11-09       Impact factor: 4.430

9.  PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population.

Authors:  Bao Zang; Chen Chen; Jian-Qiang Zhao
Journal:  Aging (Albany NY)       Date:  2020-02-21       Impact factor: 5.682

10.  Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis.

Authors:  Kaikai Zhao; Youjiao Si; Liangchao Sun; Xiangjiao Meng; Jinming Yu
Journal:  Radiat Oncol       Date:  2020-10-21       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.